Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Benzinga's Volume Movers

HRTX, BIIB, VZ, RIG, IONS

 

  • FleetMatics Group PLC (NYSE: FLTX) surged 38.8 percent to $59.63. The volume of FleetMatics shares traded was 4751 percent higher than normal. Verizon Communications Inc. (NYSE: VZ) announced plans to buy Fleetmatics at $60 per share in cash.
  • Transocean Partners LLC (NYSE: RIGP) shares moved up 8.2 percent to $11.81. The volume of Transocean Partners traded was 3494 percent higher than normal. Transocean Ltd. (NYSE: RIG) and Transocean Partners revealed Monday they have struck a deal whereby the former would buy all the outstanding units of the latter in a share-for-unit merger transaction. As a result, Transocean Partners would get 1.1427 shares of the company for every unit held.
  • Heron Therapeutics Inc (NASDAQ: HRTX) shares climbed 12.3 percent to $18.66. The volume of Heron Therapeutics shares traded was 1074 percent higher than normal. Heron Therapeutics reported top line results from two studies.
  • Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares rose 33.3 percent to $38.92. The volume of Ionis Pharmaceuticals shares traded was 695 percent higher than normal. Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals evealed that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at interim analysis of the final stage of ENDEAR trial.


Related News